Daily Anesthesiology Research Analysis
Analyzed 55 papers and selected 3 impactful papers.
Summary
Analyzed 55 papers and selected 3 impactful articles.
Selected Articles
1. NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials.
Across two multicenter, double-blind RCTs in GI endoscopy, NH600001 at 0.25 mg/kg achieved non-inferior procedure success versus etomidate 0.30 mg/kg, while the 0.20 and 0.30 mg/kg doses did not meet non-inferiority. The program assessed adrenocortical effects, consistent with the title’s finding of reduced adrenocortical depression with NH600001.
Impact: Introduces a clinically ready etomidate analogue that maintains endoscopy sedation efficacy with reduced adrenal suppression, addressing a long-standing safety limitation of etomidate.
Clinical Implications: NH600001 could become a preferred agent for GI endoscopy sedation/anesthesia where adrenal suppression is a concern, especially in patients at risk for hemodynamic instability or sepsis, pending broader regulatory approval and post-marketing safety data.
Key Findings
- In Phase II (n=160), NH600001 0.25 mg/kg was non-inferior to etomidate 0.30 mg/kg for endoscopic success (rate difference 5.0%; 95% CI −4.49 to 14.49).
- NH600001 0.20 mg/kg and 0.30 mg/kg did not meet the prespecified non-inferiority margin.
- Adrenocortical function was evaluated (cortisol AUC 0–4 h), aligning with the program’s goal to reduce etomidate-like adrenocortical depression.
Methodological Strengths
- Two multicenter, double-blind, randomized controlled trials (Phase II and III).
- Objective primary endpoint (endoscopic success) with prespecified non-inferiority margin.
Limitations
- Abstract provides incomplete quantitative details on cortisol outcomes; longer-term endocrine safety not reported.
- Population limited to GI endoscopy; generalizability to other procedural settings requires study.
Future Directions: Confirm endocrine safety and dosing in broader procedural populations; head-to-head comparisons with propofol and other sedatives; real-world effectiveness and safety registries.
To evaluate the efficacy and safety of NH600001, a novel etomidate derivative, in gastrointestinal endoscopy, as well as its impact on adrenocortical function, two multicenter, double-blind, randomized, controlled clinical trials(NH600001-21 [Phase II trial] and NH600001-31 [Phase III trial]) were conducted in China. In NH600001-21, 160 gastroscopy subjects were randomized 1:1:1:1 to receive NH600001 (0.20, 0.25, or 0.30 mg/kg) and etomidate (0.30 mg/kg). In NH600001-31, 344 gastroscopy or colonoscopy subjects were randomized in a 1:1 ratio to receive NH600001 (0.25 mg/kg) and etomidate (0.30 mg/kg). The primary efficacy outcome was the rate of endoscopic success. Additionally, Safety and effects on adrenocortical function were also assessed. In NH600001-21, the 0.25 mg/kg NH600001 showed non-inferiority to etomidate based on the prespecified non-inferiority margin of -8% (Rate Difference [95% confidence interval], 5.0[-4.49 to 14.49]), whereas the 0.20 mg/kg and 0.30 mg/kg NH600001 did not meet statistical non-inferiority criteria (0[-11.54 to 11.54]; 0[-11.54 to 11.54]). The area under curve (AUC) of plasma cortisol change values within 0-4 h (∆Cortisol AUC
2. Epidemiology, ventilation management, and clinical outcomes in children (PRoVENT-PED): first results from the 10-year, investigator-initiated, international, multicentre, prospective cohort study.
In 1,427 invasively ventilated children from 83 ICUs across 34 countries, 28-day ICU mortality was 14% and higher in PARDS (27%) than non-PARDS (12%). Ventilation practices varied by age and PARDS, and potentially modifiable factors—PEEP, driving pressure, and FiO2—were associated with outcome.
Impact: Provides the largest contemporary, prospective international characterization of pediatric ventilation, highlighting modifiable parameters linked to mortality and setting priorities for pediatric lung-protective strategies.
Clinical Implications: Focus on minimizing driving pressure, optimizing PEEP, and avoiding excessive FiO2 may improve outcomes in invasively ventilated children, especially those with PARDS; these findings justify targeted interventional trials.
Key Findings
- Among 1,427 children, PARDS prevalence was 11% and was most frequent in preschool-aged patients.
- 28-day ICU mortality was 14% overall; higher in PARDS (27%) versus non-PARDS (12%).
- Age and PARDS status were associated with exposure to higher airway pressures; PEEP, driving pressure (ΔP), and FiO2 were associated with outcomes.
Methodological Strengths
- Prospective, international, multicentre cohort with standardized data collection from routine care.
- Large sample across 83 ICUs and predefined age strata enabling generalizability.
Limitations
- Observational design limits causal inference; residual confounding possible.
- Excludes ECMO patients; ventilator parameter-outcome associations may be influenced by illness severity.
Future Directions: Randomized trials testing ΔP- and PEEP-targeted ventilation in pediatric ARDS; benchmarking and feedback programs to harmonize pediatric ventilator practices globally.
BACKGROUND: Evidence supporting lung-protective ventilation in children overwhelmingly stems from adult trials. This study aimed to assess the epidemiology, ventilation management, and outcomes across predefined age groups of invasively ventilated critically ill children with or without paediatric acute respiratory distress syndrome (PARDS), and to identify potentially modifiable factors associated with outcome. METHODS: This 10-year, investigator-initiated, international, multicentre, observational prospective cohort study was conducted in 83 ICUs across 34 countries worldwide. Paediatric intensive care units were invited to participate in a registry. This phase of the study enrolled children (younger than 18 years) admitted to a participating centre who received invasive ventilation for at least 12 h. Preterm infants of a postconceptional age younger than 40 weeks and those receiving extracorporeal membrane oxygenation were excluded from participation. All data collected, including patient demographics, baseline characteristics, and ventilation data, were part of standard clinical care and retrieved from medical records. The primary outcome was 28-day intensive care unit (ICU) mortality. This study is registered at ClinicalTrials.gov (NCT06220825), the first phase of the study is completed, subsequent phases on different topics are currently running. FINDINGS: 1427 children (median age 24 months [IQR 7-96]; 799 [56%] were male and 628 [44%] were female) were enrolled between April 1, and June 30, 2024, and Oct 1, and Dec 31, 2024. PARDS was identified in 164 (11%) of 1427 children and occurred most frequently in preschool-aged children (aged 3 years to younger than 6 years). Ventilator management varied by age and PARDS status; decreased age and the presence of PARDS were associated with exposure to high airway pressures. 28-day ICU mortality was 14% (201 of 1427 children), and it was lowest in neonates (3 [3%] of 112 children) and higher in patients with PARDS than those without PARDS (44 [27%] of 164 vs 157 [12%] of 1263). Positive end-expiratory pressure (PEEP), driving pressure (ΔP) and fractional concentration of oxygen (FiO
3. General versus spinal anesthesia and early functional and discharge outcomes after geriatric total joint arthroplasty: an NSQIP database retrospective cohort study.
In 62,338 geriatric THA/TKA cases, general anesthesia was associated with higher odds of early ADL decline (aOR 1.32) and non-home discharge (aOR 1.70) than spinal anesthesia, consistent across hip and knee subgroups.
Impact: Highlights anesthetic technique as a modifiable factor linked to meaningful recovery metrics in older adults after joint arthroplasty, leveraging a large, contemporary national dataset.
Clinical Implications: When feasible, spinal anesthesia may be preferred to reduce early functional decline and facilitate home discharge in older adults undergoing elective THA/TKA; shared decision-making should incorporate these outcome differences.
Key Findings
- Among 62,338 cases (GA 30,296; SA 32,042), GA had higher functional decline (38.5% vs 30.2%; p<0.001).
- GA was associated with increased odds of functional decline (aOR 1.32; 95% CI 1.28–1.37) and non-home discharge (aOR 1.70; 95% CI 1.63–1.78).
- Findings were consistent across both THA and TKA cohorts.
Methodological Strengths
- Very large sample size with contemporary national registry (NSQIP) data.
- Multivariable adjustment to address confounding with consistent subgroup results.
Limitations
- Retrospective observational design subject to residual confounding and selection bias in anesthetic choice.
- Lacks granular intraoperative details (e.g., specific anesthetic agents, hemodynamics) that could influence outcomes.
Future Directions: Prospective comparative effectiveness studies and pragmatic trials to confirm causality; exploration of mechanisms linking anesthetic technique to functional recovery.
BACKGROUND: Older adults undergoing total joint arthroplasty (TJA) are particularly vulnerable to postoperative functional decline, yet the impact of anesthetic technique on recovery remains uncertain. This study examined whether spinal anesthesia (SA), compared with general anesthesia (GA), is associated with early functional decline and non-home discharge in geriatric patients undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA). METHODS: We performed a retrospective cohort study using the 2021-2023 American College of Surgeons National Surgical Quality Improvement Program database. Patients aged ≥75 years undergoing THA or TKA were included. The primary outcome was functional status decline, defined as any reduction in activities of daily living independence from preoperative status to hospital discharge. The secondary outcome was discharge disposition, categorized as home versus non-home. Multivariable logistic regression was used to estimate adjusted ORs (aORs) for associations between anesthetic type and outcomes. RESULTS: The cohort included 62 338 cases (GA: 30 296; SA: 32 042). GA was associated with higher rates of functional decline (38.5% vs 30.2%; p<0.001) and non-home discharge (22.6% vs 11.0%; p<0.001). After adjustment, GA remained independently associated with increased odds of functional decline (aOR 1.32; 95% CI 1.28 to 1.37; p<0.001) and non-home discharge (aOR 1.70; 95% CI 1.63 to 1.78; p<0.001). Findings were consistent across THA and TKA subgroups. CONCLUSION: In patients aged 75 years or older undergoing elective total joint arthroplasty, general anesthesia was associated with significantly higher odds of early functional decline and discharge to a non-home setting compared with spinal anesthesia. These findings suggest that anesthetic choice may be a modifiable perioperative factor for optimizing recovery in geriatric total hip arthroplasty patients.